Company profile: Quell Therapeutics
1.1 - Company Overview
Company description
- Provider of engineered regulatory T cell (Treg) therapies for solid organ transplant and autoimmune diseases. Develops QEL-001 to prevent liver transplant rejection without lifelong immunosuppression and, with AstraZeneca, engineered Treg therapies for Type 1 Diabetes and Inflammatory Bowel Disease. Offers a modular platform using proprietary technologies to enhance Tregs, target specific antigens, and direct them to specific body targets.
Products and services
- Modular Engineered Treg Cell Therapies: Proprietary platform enhances engineered Tregs to target specific antigens and direct them to particular body targets
- QEL-001: Engineered Treg cell therapy aims to prevent organ rejection in liver transplant patients without lifelong immunosuppression
- Engineered Treg Cell Therapies for Autoimmune Diseases: Engineered therapies, developed with AstraZeneca, utilize Treg cells for Type 1 Diabetes and Inflammatory Bowel Disease indications
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Quell Therapeutics
OSE Immunotherapeutics
HQ: France
Website
- Description: Provider of immunotherapies in immuno-oncology, auto-immune diseases, and transplantation, with a pipeline including Tedopi (Phase 3 cancer vaccine for NSCLC resistant to checkpoint inhibitors), OSE-279 (anti-PD1), BI 765063/OSE-172 (SIRPα), OSE-127 (IL-7R; ulcerative colitis), FR104 (CD28; renal transplantation), and OSE-230 (ChemR23; chronic inflammatory diseases).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full OSE Immunotherapeutics company profile →
Oxford Immunotec
HQ: United Kingdom
Website
- Description: Provider of medical diagnostic tests based on patented T cell measurement technology, including T-SPOT.TB, an interferon gamma release assay for diagnosing latent TB infection and TB disease; T-SPOT.CMV for detecting cytomegalovirus infections; and T-SPOT.PRT for assessing immune responses to various pathogens.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Oxford Immunotec company profile →
Paragonix Technologies
HQ: United States
Website
- Description: Provider of organ preservation and transport systems for heart, lung, and liver transplantation, including FDA-cleared SherpaPak Cardiac Transport System and LUNGguard, LIVERguard for static hypothermic liver preservation, and BAROguard with automated pressure regulation, plus a digital app for real-time location and temperature tracking and 24/7 clinical support for procurement and organ delivery.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Paragonix Technologies company profile →
Verici Dx
HQ: United States
Website
- Description: Provider of RNA signature-based diagnostics for kidney transplant patients, offering pre- and post-transplant prognostic tests—Clarava to predict early rejection risk and Tutivia to assess post-transplant rejection risk—and RNA Signature Tests that provide insights into immune response and transplant prognosis, while tracking patient records and the patient journey.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Verici Dx company profile →
XVIVO Perfusion
HQ: Sweden
Website
- Description: Provider of medical technology solutions for organ, tissue, and cell preservation in transplantation, offering the XPS ex‑vivo lung perfusion system, Kidney Assist Transport for hypothermic pulsatile perfusion, Liver Assist protocols, PERFADEX Plus lung preservation solution, and the XVIVO Academy to improve transplant outcomes and support transplant teams.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full XVIVO Perfusion company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Quell Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Quell Therapeutics
2.2 - Growth funds investing in similar companies to Quell Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Quell Therapeutics
4.2 - Public trading comparable groups for Quell Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →